Q4 2024 Holdings
Filed 2025-02-13 | 11 holdings | $410.1M | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Arcellx, Inc.(ACLX) | Common Stock | 03940C100 | $180.0M | 2,346,630 | 43.9% |
| ARS Pharmaceuticals, Inc.(SPRY) | Common Stock | 82835W108 | $42.3M | 4,012,903 | 10.3% |
| Crispr Therapeutics AG(CRSP) | Common Shares | H17182108 | $41.3M | 1,048,951 | 10.1% |
| Design Therapeutics, Inc.(DSGN) | Common Stock | 25056L103 | $40.3M | 6,526,476 | 9.8% |
| Zenas BioPharma, Inc(ZBIO) | Common Stock | 98937L105 | $40.2M | 4,911,539 | 9.8% |
| Mineralys Therapeutics Inc.(MLYS) | Common Stock | 603170101 | $24.8M | 2,016,822 | 6.1% |
| Alumis Inc.(ALMS) | Common Stock | 022307102 | $15.4M | 1,959,896 | 3.8% |
| Oruka Therapeutics, Inc(ORKA) | Common Stock | 687604108 | $8.3M | 430,330 | 2.0% |
| Nkarta, Inc.(NKTX) | Common Stock | 65487U108 | $8.3M | 3,333,333 | 2.0% |
| enGene Holdings Inc.(ENGN) | Common Shares | 29286M105 | $5.0M | 747,750 | 1.2% |
| Kala Bio, Inc.(KALA) | Common Stock | 483119202 | $4.2M | 598,940 | 1.0% |